FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1142-1143 April 25, 1996 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Edited by Steven R. Hirsch and Daniel R. Weinberger. 740 pp. Cambridge, Mass., Blackwell Science, 1995. $125. ISBN 0-632-03276-6.

Schizophrenia is widely regarded as the most disabling psychiatric disorder, but scientific knowledge about its pathogenesis and treatment has been acquired relatively recently. In the 1950s, half a century after Kraepelin and Bleuler defined the characteristics and course of schizophrenia, the serendipitous discovery of the antipsychotic effects of chlorpromazine ushered in the neuropharmacologic era. The 1970s brought a new understanding of the role of neurotransmitters and the epidemiology of the illness. In the 1980s, the development of brain-imaging techniques allowed investigators to probe abnormalities in the structure and function of the brain in schizophrenia and fueled the development of new . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.